Abstract:As a novel co-receptor for vascular endothelial growth factor (VEGF), neuropilin receptor type-1 (NRP-1) is overexpressed in several cancers and metastases, and serves as an attractive target for cancer molecular imaging and therapy. Previous single photon emission computerized tomography (SPECT) studies demonstrated that the small NRP-1-targeting peptides 99mTc-MA-ATWLPPR and 99mTc-CK3 showed poor tumor imaging quality, because of their rapid blood clearance and very low tumor uptake. Compared with small peptides, monoclonal antibodies (mAbs) can improve imaging of NRP-1-expression, due to their high affinity, specificity and slow extraction. A6-11-26 is a novel monoclonal antibody against NRP-1 b1b2 domain that exhibits inhibition of tumor growth in NPR-1-expressing preclinical models. The aim of the present study was to develop the 131I-labeled anti-NRP-1 monoclonal antibody A6-11-26 as a SPECT probe for imaging of NRP-1-positive tumor. An anti-NRP-1 monoclonal antibody (A6-11-26) was produced by hybridomas and was labeled with iodine-131 by the iodogen method. In vitro, the radiolabeling efficiency, radiochemical purity, immunoreactive fraction and stability were assessed. Binding affinity and specificity of 131I‑A6-11-26 to NRP-1 were evaluated using human glioblastoma U87MG cells. In vivo, biodistribution and SPECT/CT studies were conducted on mice bearing U87MG xenografts after the injection of 131I-A6-11-26 with or without co-injection of unlabeled A6-11-26 antibody. A6-11-26 was generated successfully by hybridoma with high purity (>95%) and was labeled with iodine-131 within 60 min with high labelling efficiency (95.46±3.34%), radiochemical purity (98.23±1.41%). 131I-A6-11-26 retained its immunoreactivity and also displayed excellent stability in mouse serum and PBS solution during 1 to 96 h. Cell uptake assays showed high NRP-1-specific uptake (15.80±1.30% applied activity at 6 h) in U87MG cells. 131I-A6-11-26 bound to NRP-1 with low nanomolar affinity (KD=1.67±0.14 nM) in U87MG cells. In vivo, biodistribution study demonstrated targeting of U87MG glioma xenografts was NRP-1 specific. The tumor uptake was 6.00±1.24%ID/g at 24 h, and the tumor to muscle ratio was 3.20±0.30 at 24 h, and reached the highest level of 6.13±0.24 at 120 h after injection. SPECT imaging studies revealed that 131I-A6-11-26 could clearly identify U87MG tumors with good contrast, especially at 72-120 h after injection. The present study demonstrates that 131I-A6-11-26 is capable of detecting lesions in an NRP-1-expressing tumor with high target selectivity, and may offer a promising SPECT agent for NRP-1 expression positive tumor and encourage further investigation.

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

Biodistribution of ~(131)I-D_2C_5 in nude mice bearing tumor

Tumor Radioimmunoimaging of Chimeric Antibody in Nude Mice with Hepatoma Xenograft.

Biodistribution and Imaging of Radioiodinate Antihuman Tumor-derived IgG Light Chain Monoclonal Antibody in Nude Mice Bearing Tumor in Vivo

Radiolabeling and animal experimental studies of anti-breast cancer McAb 6C6 and mouse-human chimeric antibody 6C6CHI

Study of Distribution and Antisense Imaging for 99Mtc-Ason-egf in Breast Cancer-Bearing Nude Mouse Models

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

SPECT Imaging of Neuropilin Receptor Type-1 Expression with 131I-Labeled Monoclonal Antibody.

Radioimmunotherapy of Human Colon Cancer Xenografts with<sup>131</sup>I-Labeled Anti-CEA Monoclonal Antibody

Radiolabeled AIE Probes As Dual-modality Imaging Agents for PET/NIR-II Fluorescence-Guided Photothermal Therapy

Radiolabelling and Biological Evaluation of 99Tcm-Mab109 Against Breast Cancer

EXPERIMENTAL STUDY OF RADIOIMMUNOIMAGING WITH 99mtc LABELING F(ab')2 FRAGMENT

Experimental Study on Radioiodine Labeled Anti-PD-L1 Monoclonal Tibody As Novel Tumor Immunosuppressive Agent Imaging Probe

Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody.

99Tcm-Tp5-3 Microspect/ct for the Early Evaluation of Response in Mice Bearing MDA-MB-231 Breast Carcinoma after a Single Dose of Paclitaxel Chemotherapy

[Research on Radioimmunotherapy of Lung Cancer in Nude Mice Using Lung Cancer Monoclonal Antibody LC-1 Combined with ⁹⁰Y].

Inhibitory effect 131I-antiAFP McAb-DOX-BSA nanoparticles on hepatocellular carcinoma bearing nude mice

Radioiodination, Purification, and Evaluation of Antihuman Tumor-Derived Immunoglobulin G Light Chain Monoclonal Antibody in Tumor-Bearing Nude Mice.

Research on Radioimmunotherapy of Lung Cancer in Nude Mice Using Lung Cancer Monoclonal Antibody LC-1 Combined with 90Y